Novartis 'completely committed' to Sandoz, has no split-off plan

Novartis 'completely committed' to Sandoz, has no split-off plan

Source: 
Yahoo/Reuters
snippet: 

 Swiss drugmaker Novartis (NOVN.S) is "completely committed" to its $10 billion-per-year Sandoz generics business, a spokesman said on Thursday, after a newspaper reported Chief Executive Vas Narasimhan planned to split the unit off.